Monaco Asset Management SAM Has $1.20 Million Stock Position in Inogen, Inc (NASDAQ:INGN)

Monaco Asset Management SAM lifted its holdings in shares of Inogen, Inc (NASDAQ:INGN) by 119.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 167,594 shares of the medical technology company’s stock after purchasing an additional 91,094 shares during the quarter. Monaco Asset Management SAM owned approximately 0.62% of Inogen worth $1,195,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Ameriprise Financial Inc. grew its stake in Inogen by 0.6% in the 4th quarter. Ameriprise Financial Inc. now owns 848,980 shares of the medical technology company’s stock valued at $7,785,000 after buying an additional 5,148 shares during the last quarter. Bridgeway Capital Management LLC grew its stake in Inogen by 4.7% in the 4th quarter. Bridgeway Capital Management LLC now owns 631,230 shares of the medical technology company’s stock valued at $5,788,000 after buying an additional 28,517 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Inogen by 25.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company’s stock valued at $5,574,000 after buying an additional 123,208 shares during the last quarter. Renaissance Technologies LLC grew its stake in Inogen by 17.9% in the 4th quarter. Renaissance Technologies LLC now owns 492,900 shares of the medical technology company’s stock valued at $4,520,000 after buying an additional 75,000 shares during the last quarter. Finally, Royce & Associates LP grew its stake in Inogen by 42.8% in the 1st quarter. Royce & Associates LP now owns 444,457 shares of the medical technology company’s stock valued at $3,169,000 after buying an additional 133,258 shares during the last quarter. Institutional investors and hedge funds own 89.94% of the company’s stock.

Analyst Ratings Changes

INGN has been the topic of a number of research analyst reports. B. Riley initiated coverage on shares of Inogen in a research note on Monday, June 16th. They issued a “buy” rating and a $14.00 target price on the stock. Stifel Nicolaus lowered their target price on shares of Inogen from $10.00 to $7.00 and set a “hold” rating on the stock in a research note on Thursday, May 8th. Finally, Needham & Company LLC upgraded shares of Inogen from a “hold” rating to a “moderate buy” rating and set a $12.00 target price on the stock in a research note on Thursday, May 22nd.

Inogen Price Performance

Shares of Inogen stock opened at $6.60 on Wednesday. Inogen, Inc has a fifty-two week low of $5.70 and a fifty-two week high of $13.33. The firm has a fifty day moving average price of $6.72 and a two-hundred day moving average price of $7.81. The company has a market cap of $177.47 million, a PE ratio of -5.74 and a beta of 1.66.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.27. Inogen had a negative net margin of 8.08% and a negative return on equity of 14.76%. The firm had revenue of $82.28 million during the quarter, compared to the consensus estimate of $79.57 million. Analysts expect that Inogen, Inc will post -1.73 earnings per share for the current fiscal year.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.